The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials

touchEXPERT OPINIONS for touchONCOLOGY

Three internationally renowned multiple myeloma experts share insights into the unmet treatment needs for patients with relapsed/refractory multiple myeloma, the rationale for emerging protein degradation and immunomodulation-based therapies, and the latest data and ongoing clinical trials for these investigational agents.  

The experts

• Prof. Cristina Gasparetto - Duke Cancer Institute, Durham, NC, USA
• Prof. Sagar Lonial - Emory University, Atlanta, GA, USA
• Prof. Sundar Jagannath - Tisch Cancer Institute, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchoncologyime.org/eo-in-rrmm